Humbert, MarcSimonneau, GéraldPittrow, DavidDelcroix, MarionPepke-Zaba, JoannaLangleben, DavidMielniczuk, Lisa M.Escribano Subias, PilarSnijder, Repke J.Barberà i Mir, Joan AlbertKlotsche, JensMeier, ChristianHoeper, Marius M2023-04-212023-04-212022-02-111053-2498https://hdl.handle.net/2445/197012EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study in patients with pulmonary hypertension treated with riociguat. Patients were followed for 1-4 years, and the primary outcomes were adverse events (AEs) and serious AEs (SAEs), including embolic/thrombotic and hemorrhagic events. Here we report data on patients with chronic thromboembolic pulmonary hypertension (CTEPH) receiving a vitamin K antagonist (VKA; n = 683) or a non-vitamin K antagonist oral anticoagulant (NOAC; n = 198) at baseline. AEs and SAEs were reported in 438 patients (64.1%) and 257 patients (37.6%), respectively, in the VKA group, and in 135 patients (68.2%) and 74 patients (37.4%) in the NOAC group. Exposure-adjusted hemorrhagic event rates were similar in the two groups, while exposure-adjusted embolic and/or thrombotic event rates were higher in the NOAC group, although the numbers of events were small. Further studies are required to determine the long-term effects of anticoagulation strategies in CTEPH.6 p.application/pdfengcc-by-nc-nd (c) Humbert, Marc et al., 2022https://creativecommons.org/licenses/by-nc-nd/4.0/Hipertensió pulmonarMalalties cròniquesAnticoagulants (Medicina)Efectes secundaris dels medicamentsVitamines KPulmonary hypertensionChronic diseasesAnticoagulants (Medicine)Drug side effectsVitamin Kinfo:eu-repo/semantics/article7334092023-04-21info:eu-repo/semantics/openAccess35305871